Aankondiging • 20h
OneSource Specialty Pharma Limited Announces Executive Changes, Effective July 24, 2026 OneSource Specialty Pharma Limited had designated Preeti Kalra (Head - Human Resources) as a Senior Management Personnel of the Company effective July 24, 2026. Preeti Kalra is an HR leader with 25+ years of experience across Biopharma, Global Development (Not-for-Profit), Public Services, Insurance, GCC and IT. She has extensive leadership experience with organizations including Stelis Biopharma, Biocon Biologics, Bill & Melinda Gates Foundation, Serco and Ernst & Young. She has expertise in business partnering, talent management, leadership development, organizational transformation, culture, organization effectiveness and change management. She has a proven track record of enabling business growth by building high-performing teams, strengthening leadership capability and driving organizational effectiveness across Asia-Pacific, Middle East, Africa, Europe and North America. OneSource Specialty Pharma Limited had Ravi Kumar (Global Head – Injectables/Head of Corporate Strategy, Portfolio & SPO), Senior Management Personnel of the Company, resign from his position effective July 24, 2026. New Risk • Jul 26
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Less than 1 year of cash runway based on current free cash flow (-₹5.6b). Reported Earnings • Jul 25
First quarter 2027 earnings released: EPS: ₹2.18 (vs ₹0.02 loss in 1Q 2026) First quarter 2027 results: EPS: ₹2.18 (up from ₹0.02 loss in 1Q 2026). Revenue: ₹4.53b (up 38% from 1Q 2026). Net income: ₹250.0m (up ₹251.8m from 1Q 2026). Profit margin: 5.5% (up from net loss in 1Q 2026). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in India. Aankondiging • Jul 21
OneSource Specialty Pharma Limited Recalls Methohexital Sodium for Injection OneSource Specialty Pharma Limited manufactured Methohexital Sodium for Injection, USP 500 mg Multiple Dose Vial, Rx Only, for Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, NDC 23155-893-31. The US Food and Drug Administration issued an enforcement report for the recall of Methohexital Sodium for Injection, USP 500 mg Multiple Dose Vial, Rx Only, manufactured by OneSource Specialty Pharma Limited, Bengaluru - 561 203, India, and manufactured for Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, NDC 23155-893-31. The reason for recall was failed impurities/degradation specifications. The product quantity affected was 4,284 vials. The recall number is D-0662-2026. Code information includes Lot #: 7000612A, Exp. Date January 2028. The recall is classified as Class II. Event details include Event ID: 99220. The recall was voluntary and firm initiated. The product type is drugs. Initial firm notification of consignee or public was by letter. The recall status is ongoing. The distribution pattern is nationwide within the United States. The recall initiation date was June 7, 2026. The center classification date was July 7, 2026. Aankondiging • Jul 20
OneSource Specialty Pharma Limited to Report Q1, 2027 Results on Jul 24, 2026 OneSource Specialty Pharma Limited announced that they will report Q1, 2027 results on Jul 24, 2026 Reported Earnings • May 14
Full year 2026 earnings: EPS and revenues exceed analyst expectations Full year 2026 results: ₹6.44 loss per share (further deteriorated from ₹1.57 loss in FY 2025). Revenue: ₹14.4b (flat on FY 2025). Net loss: ₹738.0m (loss widened 327% from FY 2025). Revenue exceeded analyst estimates by 6.0%. Earnings per share (EPS) also surpassed analyst estimates by 35%. Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Life Sciences industry in India. Aankondiging • May 07
OneSource Specialty Pharma Limited to Report Q4, 2026 Results on May 13, 2026 OneSource Specialty Pharma Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 13, 2026 Buy Or Sell Opportunity • May 05
Now 20% undervalued Over the last 90 days, the stock has risen 44% to ₹1,748. The fair value is estimated to be ₹2,191, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 72% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 115% in 2 years. Earnings are forecast to grow by 3,193% in the next 2 years. Major Estimate Revision • Feb 04
Consensus estimates of losses per share improve by 19% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₹13.1b to ₹13.4b. EPS estimate increased from -₹12.10 per share to -₹9.83 per share. Life Sciences industry in India expected to see average net income growth of 20% next year. Consensus price target down from ₹2,336 to ₹1,947. Share price rose 5.1% to ₹1,214 over the past week. Major Estimate Revision • Jan 30
Consensus revenue estimates fall by 24% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from ₹17.6b to ₹13.3b. Forecast loss of -₹12.10, down from profit of ₹24.40 per share profit previously. Life Sciences industry in India expected to see average net income growth of 20% next year. Consensus price target down from ₹2,531 to ₹2,053. Share price fell 17% to ₹1,195 over the past week. Price Target Changed • Jan 27
Price target decreased by 7.7% to ₹2,336 Down from ₹2,531, the current price target is an average from 4 analysts. New target price is 103% above last closing price of ₹1,151. Stock is down 25% over the past year. The company is forecast to post a net loss per share of ₹12.10 next year compared to a net loss per share of ₹1.57 last year. Buy Or Sell Opportunity • Jan 26
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 21% to ₹1,432. The fair value is estimated to be ₹1,791, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 72% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 136% in 2 years. Earnings are forecast to grow by 4,127% in the next 2 years. Reported Earnings • Jan 24
Third quarter 2026 earnings: EPS and revenues miss analyst expectations Third quarter 2026 results: ₹7.74 loss per share (further deteriorated from ₹6.31 loss in 3Q 2025). Revenue: ₹2.90b (down 26% from 3Q 2025). Net loss: ₹887.0m (loss widened 29% from 3Q 2025). Revenue missed analyst estimates by 30%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Aankondiging • Jan 19
OneSource Specialty Pharma Limited to Report Q3, 2026 Results on Jan 23, 2026 OneSource Specialty Pharma Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Jan 23, 2026 Reported Earnings • Nov 12
Second quarter 2026 earnings released: EPS: ₹0.92 (vs ₹6.31 loss in 2Q 2025) Second quarter 2026 results: EPS: ₹0.92 (up from ₹6.31 loss in 2Q 2025). Revenue: ₹3.79b (down 3.5% from 2Q 2025). Net income: ₹104.9m (up ₹793.3m from 2Q 2025). Profit margin: 2.8% (up from net loss in 2Q 2025). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Aankondiging • Nov 05
OneSource Specialty Pharma Limited to Report Q2, 2026 Results on Nov 11, 2025 OneSource Specialty Pharma Limited announced that they will report Q2, 2026 results at 12:08 PM, Indian Standard Time on Nov 11, 2025 Aankondiging • Sep 01
OneSource Specialty Pharma Limited, Annual General Meeting, Sep 22, 2025 OneSource Specialty Pharma Limited, Annual General Meeting, Sep 22, 2025, at 17:00 Indian Standard Time. Reported Earnings • Aug 05
First quarter 2026 earnings released: ₹0.02 loss per share (vs ₹7.90 loss in 1Q 2025) First quarter 2026 results: ₹0.02 loss per share (improved from ₹7.90 loss in 1Q 2025). Revenue: ₹3.27b (up 318% from 1Q 2025). Net loss: ₹1.86m (loss narrowed 99% from 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Aankondiging • Jul 29
OneSource Specialty Pharma Limited to Report Q1, 2026 Results on Aug 04, 2025 OneSource Specialty Pharma Limited announced that they will report Q1, 2026 results on Aug 04, 2025 New Risk • Jun 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₹2.0b free cash flow). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). New Risk • May 21
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹2.0b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company. Reported Earnings • May 07
Full year 2025 earnings released: ₹1.57 loss per share (vs ₹88.02 loss in FY 2024) Full year 2025 results: ₹1.57 loss per share (improved from ₹88.02 loss in FY 2024). Revenue: ₹14.6b (up ₹12.9b from FY 2024). Net loss: ₹172.8m (loss narrowed 95% from FY 2024). Aankondiging • Apr 30
OneSource Specialty Pharma Limited to Report Q4, 2025 Results on May 05, 2025 OneSource Specialty Pharma Limited announced that they will report Q4, 2025 results on May 05, 2025 Board Change • Apr 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. CEO, MD & Director Neeraj Sharma is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Aankondiging • Feb 28
OneSource Specialty Pharma Limited Announces Cessation of Directors OneSource Specialty Pharma Limited at its board meeting held on February 27, 2025, approved the following directors have step down from the position of directorship effective from February 27, 2025, Dr. GopaKumar Gopalan Nair as Non-Executive Independent Director, Ms. Rajashri Santosh Kumar Ojha as Non-Executive Independent Director, Mr. Mahadevan Narayanamoni as Non-Executive Independent Director and Mr. Bhushan Sudhir Bopardikar as Non-Executive Independent Director of the company. Aankondiging • Feb 21
OneSource Specialty Pharma Limited Announces Termination of Jason T Spacek, Chief Business Officer OneSource Specialty Pharma Limited announced that Mr. Jason T Spacek, Chief Business Officer, ceased to be a Senior Management Personnel with effect from February 20, 2025, consequent to his termination. Date of Cessation February 20, 2025. Aankondiging • Feb 15
Onesource Specialty Pharma Limited Approves Appointment of Bernhard Thurnbauer as Chief Quality Officer, Effective March 01, 2025 The Board of Directors of OneSource Specialty Pharma Limited via Circulation on February 14, 2025 have considered and approved the appointment of Mr. Bernhard Thurnbauer as the Chief Quality Officer (CQO) of the Company effective from March 01, 2025. Reason for change: Appointment of Mr. Bernhard Thurnbauer as the Chief Quality Officer (CQO) of the Company in line with the Internal Governance Structure of the Company. Bernhard Thurnbauer is a highly accomplished pharmaceutical executive with over 30 years of leadership experience in quality assurance, compliance, and technical operations. He has held senior positions in global biotech and pharmaceutical companies, including Moderna, Roche, Acino, and B. Braun. His expertise spans sterile injectables, biologics, CDMO operations, and regulatory compliance across USFDA, EMA, and other global health authorities. As Chief Quality Officer at OneSource, Bernhard would lead the company's global quality strategy, ensuring the highest regulatory and operational excellence. His vision focuses on developing high performing teams, transforming quality processes through artificial intelligence and aligning quality with business growth. Before joining OneSource, Bernhard was the Global Head of Audit Program Management at Moderna, overseeing a US-based team responsible for ensuring compliance with stringent global regulatory requirements. He played a pivotal role in shaping audit strategies, implementing risk-based approaches and driving efficiency improvements. Earlier in his career, Bernhard founded a manufacturing IT and compliance consultancy in Bangkok, leveraging his extensive industry experience to help pharmaceutical companies optimize operations. He is an active member of professional organizations such as ISPE and PDA. Outside of work, Bernhard enjoys traveling, exploring different cultures, and spending time by the sea. Recent Insider Transactions • Feb 08
Insider recently sold ₹74m worth of stock On the 31st of January, Vineetha Pillai sold around 48k shares on-market at roughly ₹1,565 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹104m more than they bought in the last 12 months. Reported Earnings • Jan 31
Third quarter 2025 earnings released Third quarter 2025 results: ₹6.31 loss per share. Net loss: ₹688.5m (flat on 3Q 2024). 
